Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Inhibition of HIF-prolyl-4-hydroxylases prevents mitochondrial impairment and cell death in a model of neuronal oxytosis.

Neitemeier S, Dolga AM, Honrath B, Karuppagounder SS, Alim I, Ratan RR, Culmsee C.

Cell Death Dis. 2016 May 5;7:e2214. doi: 10.1038/cddis.2016.107.

2.

Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases.

Karuppagounder SS, Kumar A, Shao DS, Zille M, Bourassa MW, Caulfield JT, Alim I, Ratan RR.

Brain Res. 2015 Dec 2;1628(Pt B):273-87. doi: 10.1016/j.brainres.2015.07.030. Review.

PMID:
26232572
3.

Profiling of Proteins Regulated by Venlafaxine during Neural Differentiation of Human Cells.

Doh MS, Han DM, Oh DH, Kim SH, Choi MR, Chai YG.

Psychiatry Investig. 2015 Jan;12(1):81-91. doi: 10.4306/pi.2015.12.1.81.

4.

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

Aleyasin H, Karuppagounder SS, Kumar A, Sleiman S, Basso M, Ma T, Siddiq A, Chinta SJ, Brochier C, Langley B, Haskew-Layton R, Bane SL, Riggins GJ, Gazaryan I, Starkov AA, Andersen JK, Ratan RR.

Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. doi: 10.1089/ars.2013.5595.

5.

Elevated arteriolar cerebral blood volume in prodromal Huntington's disease.

Hua J, Unschuld PG, Margolis RL, van Zijl PC, Ross CA.

Mov Disord. 2014 Mar;29(3):396-401. doi: 10.1002/mds.25591.

6.

Prolyl 4 hydroxylase: a critical target in the pathophysiology of diseases.

Kant R, Bali A, Singh N, Jaggi AS.

Korean J Physiol Pharmacol. 2013 Apr;17(2):111-20. doi: 10.4196/kjpp.2013.17.2.111.

7.

In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.

Karuppagounder SS, Basso M, Sleiman SF, Ma TC, Speer RE, Smirnova NA, Gazaryan IG, Ratan RR.

J Neurosci Res. 2013 Aug;91(8):1066-75. doi: 10.1002/jnr.23204.

8.

Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.

Speer RE, Karuppagounder SS, Basso M, Sleiman SF, Kumar A, Brand D, Smirnova N, Gazaryan I, Khim SJ, Ratan RR.

Free Radic Biol Med. 2013 Sep;62:26-36. doi: 10.1016/j.freeradbiomed.2013.01.026. Review.

9.

Rapid vascular responses to anthrax lethal toxin in mice containing a segment of chromosome 11 from the CAST/Ei strain on a C57BL/6 genetic background.

Weigel KJ, Rues L, Doyle EJ, Buchheit CL, Wood JG, Gallagher RJ, Kelly LE, Radel JD, Bradley KA, LeVine SM.

PLoS One. 2012;7(7):e40126. doi: 10.1371/journal.pone.0040126.

10.

Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R.

Antioxid Redox Signal. 2012 Dec 1;17(11):1610-55. Review.

11.

Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Zhang Z, Yan J, Chang Y, ShiDu Yan S, Shi H.

Curr Med Chem. 2011;18(28):4335-43. Review.

12.

Hypoxia-inducible factors and the prevention of acute organ injury.

Heyman SN, Rosen S, Rosenberger C.

Crit Care. 2011;15(2):209. doi: 10.1186/cc9991. Review. No abstract available.

14.

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.

McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, Ratan RR.

EMBO Mol Med. 2010 Sep;2(9):349-70. doi: 10.1002/emmm.201000084.

Items per page

Supplemental Content

Support Center